BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 28801248)

  • 1. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
    Creemers A; Krausz S; Strijker M; van der Wel MJ; Soer EC; Reinten RJ; Besselink MG; Wilmink JW; van de Vijver MJ; van Noesel CJM; Verheij J; Meijer SL; Dijk F; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):394-403. PubMed ID: 28801248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis.
    Gao Y; Zhang K; Xi H; Cai A; Wu X; Cui J; Li J; Qiao Z; Wei B; Chen L
    Oncotarget; 2017 Jan; 8(4):6330-6340. PubMed ID: 28009985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.
    Fang Z; Meng Q; Zhang B; Shi S; Liu J; Liang C; Hua J; Yu X; Xu J; Wang W
    Aging (Albany NY); 2020 Dec; 13(2):2031-2048. PubMed ID: 33318293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
    Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
    Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis.
    Min L; Chen J; Yu M; Yang K; Liu D
    Biomarkers; 2023 Dec; 28(5):427-436. PubMed ID: 37036017
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Lee JS; Rhee TM; Pietrasz D; Bachet JB; Laurent-Puig P; Kong SY; Takai E; Yachida S; Shibata T; Lee JW; Park HC; Zang DY; Jeon K; Lee J; Kim M; Kim HS; Kang HJ; Lee YK
    Sci Rep; 2019 Nov; 9(1):16971. PubMed ID: 31740696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis.
    Chidambaram S; Markar SR
    Dis Esophagus; 2022 Feb; 35(2):. PubMed ID: 34286823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
    Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
    Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.
    Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA
    J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer.
    Sellahewa R; Moghaddam SM; Lundy J; Jenkins BJ; Croagh D
    Pancreas; 2023 Mar; 52(3):e188-e195. PubMed ID: 37751379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer.
    Guven DC; Sahin TK; Yildirim HC; Aktepe OH; Dizdar O; Yalcin S
    Crit Rev Oncol Hematol; 2021 Dec; 168():103528. PubMed ID: 34800650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
    Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
    Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update of clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta-analysis.
    Zhang Y; Du H; Wang N; Wang L; Huang Y
    BMC Cancer; 2024 Jan; 24(1):129. PubMed ID: 38267901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
    Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
    Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
    Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
    Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.